Particles for inhalation having sustained release properties
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/12
A61K-009/14
출원번호
US-0094955
(2002-03-07)
발명자
/ 주소
Vanbever,Rita
Langer,Robert S.
Edwards,David A.
Mintzes,Jeffrey
Wang,Jue
Chen,Donghao
출원인 / 주소
Massachusetts Institute of Technology
The Penn State Research Foundation
대리인 / 주소
Elmore Patent Law Group, PC
인용정보
피인용 횟수 :
9인용 특허 :
106
초록▼
The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary
The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising a polycationic complexing agent which is complexed with a therapeutic, prophylactic or diagnostic agent or any combination thereof having a charge capable of complexing with the polycationic complexing agent upon association with the bioactive agent. The particles can further comprise a pharmaceutically acceptable carrier. The amount of polycationic complexing agent present in the particles is an amount sufficient to sustain the release of diagnostic, therapeutic or prophylactic agent from the particles. For example, the amount of complexing agent present can be at about 5% weight/weight (w/w) or more of the total weight of the complexing agent and therapeutic, diagnostic or prophylactic agent. Release of the agent from the administered particles occurs in a sustained fashion.
대표청구항▼
What is claimed is: 1. A method of delivery to the pulmonary system comprising: administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of a dry powder having a tap density of less than about 0.1 g/cm3 and comprising a polycationic comp
What is claimed is: 1. A method of delivery to the pulmonary system comprising: administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of a dry powder having a tap density of less than about 0.1 g/cm3 and comprising a polycationic complexing agent which is complexed with a therapeutic, prophylactic or diagnostic agent wherein, the amount of polycationic complexing agent present in the particles is about 5% weight/weight or more of the total weight of the complexing agent and therapeutic, diagnostic or prophylactic agent and wherein release of the agent is sustained. 2. The method of claim 1 wherein the dry powder further comprises a pharmaceutically acceptable carrier. 3. The method of claim 2, wherein the therapeutic, prophylactic or diagnostic agent is a protein. 4. The method of claim 3, wherein the protein is insulin. 5. The method of claim 3, wherein the polycationic complexing agent is selected from protamine, spermine, spermidine, chitosan, a polycationic polyamino acid and combinations thereof. 6. The method of claim 5, wherein the polycationic complexing agent is protamine. 7. The method of claim 3, wherein the polycationic complexing agent is present at about 10% w/w or more of the total weight of the complexing agent and therapeutic, diagnostic or prophylactic agent. 8. The method of claim 3, wherein the polycationic complexing agent is present at about 25% w/w or more of the total weight of the complexing agent and therapeutic, diagnostic or prophylactic agent. 9. The method of claim 3, wherein complexation of the complexing agent with the therapeutic, diagnostic or prophylactic agent comprises an ionic complexation. 10. The method of claim 3, wherein the dry powder have a geometric diameter of from about 5 micrometers to about 30 microns. 11. The method of claim 3, wherein the dry powder have an aerodynamic diameter of from about 1 to about 5 microns. 12. The method of claim 11, wherein the dry powder have an aerodynamic diameter of from about 1 to about 3 microns. 13. The method of claim 11, wherein the dry powder have an aerodynamic diameter of from about 3 to about 5 microns. 14. The method of claim 3, wherein delivery to the pulmonary system includes delivery to the deep lung. 15. The method of claim 3, wherein delivery to the pulmonary system includes delivery to the central airways. 16. The method of claim 3, wherein delivery to the pulmonary system includes delivery to the upper airways. 17. The method of claim 3, wherein the dry powder further comprise a carboxylic acid. 18. The method of claim 17, wherein the carboxylic acid includes at least two carboxyl groups. 19. The method of claim 18, wherein the carboxylic acid is citric acid or a salt thereof. 20. The method of claim 3, wherein the dry powder further comprise an amino acid. 21. The method of claim 20, wherein the amino acid is hydrophobic. 22. The method of claim 21, wherein the hydrophobic amino acid is leucine, isoleucine, alanine, valine, phenylalanine or any combination thereof. 23. The method of claim 3 wherein the pharmaceutically acceptable carrier is a phospholipid. 24. The method of claim 23 wherein the phospholipid is a phosphatidic acid, a phosphatidylcholine, a phosphatidylalkanolamine, a phosphatidylethanolamine, a phosphatidylglycerol, a phosphatidylserine, a phosphatidylinositol or combinations thereof. 25. A method of delivery to the pulmonary system comprising: administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of a dry powder having a tap density of less than about 0.1 g/cm3 and comprising a protein which is complexed with protamine wherein, the amount of protamine present in the particles is about 5% weight/weight or more of the total weight of protamine and therapeutic, diagnostic or prophylactic agent and wherein release of the agent is sustained. 26. The method of claim 25 wherein the dry powder further comprises a pharmaceutically acceptable eater. 27. The method of claim 26, wherein the dry powder has a tap density less than about 0.1 g/cm3 and a median geometric diameter of from about 5 microns to about 30 micrometers. 28. The method of claim 26, wherein the pharmaceutically acceptable carrier is a phospholipid. 29. The method of claim 26 wherein the dry powder further comprises a carboxylic acid. 30. A composition for the delivery of a therapeutic, prophylactic or diagnostic agent to the pulmonary system comprising: an effective amount of dry powder having a tap density of less than about 0.1 g/cm3 and having a therapeutic, prophylactic or diagnostic agent which is complexed to a polycationic complexing agent wherein the therapeutic, prophylactic or diagnostic agent has a charge which is opposite to that of the polycationic complexing agent wherein, the amount of polycationic complexing agent present in the particles is about 5% weight/weight or more of the total weight of the complexing agent and therapeutic, diagnostic or prophylactic agent. 31. The composition of claim 30 further comprising a pharmaceutically acceptable carrier. 32. The composition of claim 30, wherein the therapeutic, prophylactic or diagnostic agent is a protein. 33. The composition of claim 32, wherein the protein is insulin. 34. The composition of claim 30 wherein the polycationic complexing agent is selected from protamine, spermine, spermidine, chitosan, a polycationic polyamino acid and combinations thereof. 35. The composition of claim 31, wherein the polycationic complexing agent is protamine. 36. The composition of claim 30, wherein the polycationic complexing agent is present at 10% w/w or more of the total weight of the complexing agent and the therapeutic, prophylactic or diagnostic agent. 37. The composition of claim 30, wherein the polycationic complexing agent is present at about 25% w/w of the total weight of the complexing agent and therapeutic, prophylactic or diagnostic agent. 38. The composition of claim 30, wherein complexation of the therapeutic, prophylactic or diagnostic agent and the polycationic complexing agent comprises an ionic complexation. 39. The composition of claim 30, wherein the dry powder has an aerodynamic diameter of from about 1 to about 3 microns. 40. The composition of claim 30, wherein the dry powder has an aerodynamic diameter of from about 3 to about 5 microns. 41. The composition of claim 30 wherein the dry powder further comprises a carboxylic acid. 42. The composition of claim 41, wherein the carboxylic acid includes at least two carboxyl groups. 43. The composition of claim 42, wherein the carboxylic acid is citric acid or a salt thereof. 44. The composition of claim 30, wherein the dry powder further comprises an amino acid. 45. The composition of claim 44, wherein the amino acid is hydrophobic. 46. The composition of claim 45, wherein the hydrophobic amino acid is leucine, isoleucine, alanine, valine, phenylalanine or any combination thereof. 47. The composition of claim 31 wherein the pharmaceutically acceptable carrier is a phospholipid. 48. The composition of claim 47 wherein the phospholipid is a phosphatidic acid, a phosphatidylcholine, a phosphatidylalkanolamine, a phosphatidylethanolamine, a phosphatidylglycerol, a phosphatidylserine, a phosphatidylinositol and combinations thereof.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (106)
Edwards David A. ; Caponetti Giovanni,ITX ; Hrkach Jeffrey S. ; Lotan Noah,ILX ; Hanes Justin ; Ben-Jebria Abdell Aziz ; Langer Robert S., Aerodynamically light particles for pulmonary drug delivery.
Edwards David A. ; Caponetti Giovanni,ITX ; Hrkach Jeffrey S. ; Lotan Noah,ILX ; Hanes Justin ; Ben-Jebria Abdell Aziz ; Langer Robert S., Aerodynamically light particles for pulmonary drug delivery.
Williams David R. (San Diego CA) Mecikalski Mark B. (Tucson AZ) Thueson David O. (Poway CA), Apparatus for aerosolizing powdered medicine and process and using.
Holland John W.,AUX ; Madden Thomas D.,CAX ; Cullis Pieter R.,CAX, Bilayer stabilizing components and their use in forming programmable fusogenic liposomes.
Hilmann Juergen (Berlin DEX) Hoffmann Rolf-Ruediger (Berlin DEX) Muetzel Wolfgang (Berlin DEX) Zimmermann Ingfried (Berlin DEX), Carrier liquid solutions for the production of gas microbubbles, preparation thereof, and use thereof as contrast medium.
Platz, Robert M.; Patton, John S.; Foster, Linda; Eljamal, Mohammed, Devices compositions and methods for the pulmonary delivery of aerosolized medicaments.
Potter Dennis L. (Kernersville NC) Raker Mark L. (Clemmons NC) Ridings Henry T. (Lewisville NC) Sensabaugh ; Jr. Andrew J. (Winston-Salem NC) Westmoreland Amos E. (Winston-Salem NC) Woods Donna K. (W, Drug delivery article.
Reul Bernhard (Konigstein DEX) Petri Walter (Wiesbaden DEX), Drug formulations comprising coated, very sparingly water-soluble drugs for inhalational pharmaceutical forms, and proce.
Illum Lisbeth (Nottingham GBX), Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving mater.
Torobin Leonard B. (Materials Technology Corporation ; Tower Place/Suite 1425 ; 3340 Peachtree Rd. ; NE. Atlanta GA 30026), Hollow porous microspheres containing biocatalyst.
Radhakrishnan Ramachandran (Fremont CA) Mihalko Paul J. (Fremont CA) Abra Robert M. (San Francisco CA), Method and apparatus for administering dehydrated liposomes by inhalation.
Wise Donald L. (Belmont MA) Trantolo Debra J. (Princeton MA) Gresser Joseph D. (Brookline MA), Method for making a bioerodible material for the sustained release of a medicament and the material made from the method.
Tice Thomas R. (Birmingham AL) Gilley Richard M. (Birmingham AL) Eldridge John H. (Birmingham AL) Staas Jay K. (Birmingham AL) Hollingshead Melinda G. (Birmingham AL) Shannon William M. (Birmingham A, Method of potentiating an immune response.
Hommel Martin (Toronto CAX) Mein-Fang Sun Anthony (Willowdale CAX) Goosen Mattheus F. A. (Toronto CAX), Microcapsule composition suitable for cardiovascular injection.
Vassiliades Anthony E. (Deerfield IL) Shroff Shrenik (Lake Forest IL) Nauman Edward F. (Chicago IL), Oil-in-water emulsions containing hydropholeic starch.
Boyes Robert N. (St. Albans AL GB2) Tice Thomas R. (Birmingham AL) Gilley Richard M. (Birmingham AL) Pledger Kenneth L. (Huntsville AL), Pharmaceutical formulations comprising microcapsules.
Zuckermann Ronald N. ; Dubois-Stringfellow Nathalie ; Dwarki Varavani ; Innis Michael A. ; Murphy John E. ; Cohen Fred E. ; Uno Tetsuo, Polycationic polymers.
Muranishi Shozo (Kyoto JPX) Ikada Yoshito (Kyoto JPX) Yoshikawa Hiroshi (Kyoto JPX) Gen Shokyu (Kyoto JPX), Polylactic acid microspheres and process for producing the same.
Hyon Suong-Hyu (Uji JPX) Ikada Yoshita (Uji JPX), Polylactic acid type microspheres containing physiologically active substance and process for preparing the same.
DeLuca Patrick P. (Lexington KY) Kanke Motoko (Fukuyama JPX) Sato Toyomi (Tokyo CA JPX) Schroeder Hans G. (Encinitas CA), Porous microspheres for drug delivery and methods for making same.
Sutton Andrew D. (Ruddington GB2) Johnson Richard A. (West Bridgford GB2) Senior Peter J. (Near Melbourne GB2) Heath David (The Park GB2), Preparation of diagnostic agents.
Ek Bo R. (Stockholm SEX) Eriksson Kjell G. (Spnga SEX) Nyqvist Per Gustaf H. (Tullinge SEX) Ragnarsson Gert A. (Bro SEX), Process for the manufacture of porous cellulose matrices.
Liversidge Gary G. (West Chester PA) Cundy Kenneth C. (Pottstown PA) Bishop John F. (Rochester NY) Czekai David A. (Honeoye Falls NY), Surface modified drug nanoparticles.
Leong Helen (Atherton CA) Katz Martin (Menlo Park CA) Delk Ann (Kensington CA) Nacht Sergio (Los Altos CA) Berliner David (Atherton CA), Synthetic melanin aggregates.
Backstrom Kjell Goran Erik,SEX ; Dahlback Carl Magnus Olof,SEX ; Edman Peter,SEX ; Johansson Ann Charlotte Birgit,SEX, Systemic administration of a therapeutic preparation.
Unger Evan C. (Tucson AZ) Fritz Thomas A. (Tucson AZ) Matsunaga Terry (Tucson AZ) Ramaswami VaradaRajan (Tucson AZ) Yellowhair David (Tucson AZ) Wu Guanli (Tucson AZ), Therapeutic drug delivery systems.
Bckstrm Kjell G. E. (Lund SEX) Dahlbck Carl M. O. (Lund SEX) Edman Peter (Bjrred SEX) Johansson Ann C. B. (Lund SEX), Therapeutic preparation for inhalation.
Myles Arthur (Stow MA) Law Say-Jong (Dedham MA) Cole Frank X. (Stow MA), Use of phosphotriester intermediates for preparation of functionalized liposomes.
Wang, Binghe; Tai, Phang-Cheng; Jin, Jinshan; Hsieh, Yinghsin; Ritter, Ying-Ju; Cui, Jianmei; Chaudhary, Arpana S.; Dai, Chaofeng; Damera, Krishna; Chen, Weixuan, SecA inhibitors and methods of making and using thereof.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.